Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone versus placebo for obsessive-compulsive symptoms in stable bipolar disorder
IRCT20140926019295N3Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of risperidone in obsessive compulsive disorder (OCD) and bipolar disorder (BD) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Obsessional symptoms. Started Aug 2022; status: completed.
02
Drugs
risperidone
03
Conditions
obsessive compulsive disorder (OCD)bipolar disorder (BD)
Beyond the preview
Go deeper on IRCT20140926019295N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140926019295N3.